Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Moesin as a Biomarker of Endothelial Injury in Sepsis
2026-10-07
The 2021 study by Chen and colleagues identifies circulating moesin as a candidate biomarker associated with sepsis severity and endothelial barrier disruption. By combining patient observations, mouse models, and endothelial-cell perturbation experiments, the paper connects moesin with ROCK1/MLC and NF-κB signaling, while also showing why the finding remains a mechanistic and translational lead rather than a validated clinical test.
-
Lipidated Nanophotosensitizer Blocks Tumor EVs
2026-10-07
A 2025 Nature Cancer study developed a palmitic-acid-displayed nanophotosensitizer that traces tumor extracellular vesicles (TEVs) and disables them through light-triggered reactive oxygen species. The reported results connect local photodynamic tumor treatment with interruption of TEV-mediated communication, while the study’s animal evidence remains model-specific and does not establish clinical efficacy.
-
Carbenoxolone Disodium Product Overview
2026-10-06
Carbenoxolone disodium (SKU A8389) is listed by APExBIO as an 11β-hydroxysteroid dehydrogenase inhibitor for conceptual research on glucocorticoid access, gap junction communication, and related signaling. No matched paper evidence was supplied.
-
HotStart 2X Green qPCR Master Mix Overview
2026-10-06
A concise, source-limited overview of APExBIO’s HotStart™ 2X Green qPCR Master Mix (SKU K1070), covering its documented identity, conceptual scope, and evidence limitations.
-
Dynasore and FnEVs in Colorectal Cancer Research
2026-10-05
A source-grounded overview of Dynasore as a dynamin GTPase inhibitor and its conceptual relevance to research on Fusobacterium nucleatum extracellular vesicles, colorectal cancer colonization, membrane trafficking, and endocytosis. The discussion separates reported findings from hypotheses and emphasizes evidence limits.
-
Exogenous NADH Potentiates Antibiotics Against E. tarda
2026-10-05
A 2024 Virulence study reports that exogenous NADH reprogrammed Edwardsiella tarda metabolism, increased ATP-associated energy availability, and strengthened the bactericidal activity of neomycin and other antibiotic classes. The findings support a metabolic-adjuvant concept, but the evidence remains preclinical and does not establish clinical dosing, safety, or universal reversal of antibiotic resistance.
-
T7 RNA Polymerase: From RNA Yield to Function
2026-10-04
T7 RNA Polymerase is more than a high-output in vitro transcription enzyme: transcript ends, processing, and biological activity determine whether synthesized RNA performs as intended. This evidence-focused analysis connects APExBIO’s K1083 product profile with a 2025 cell-free translation study while defining the limits of what the findings demonstrate.
-
InstaBlue Protein Stain Solution: Product Overview
2026-10-03
InstaBlue Protein Stain Solution is a supplier-described Coomassie Brilliant Blue reagent for visualizing protein bands in polyacrylamide gels. No matched paper evidence was provided, so performance and broader applications remain unverified.
-
Anti Reverse Cap Analog: Assay Reliability
2026-10-02
This scenario-driven guide explains how Anti Reverse Cap Analog (ARCA), 3´-O-Me-m7G(5')ppp(5')G (SKU B8175) can reduce an important upstream source of variability in synthetic mRNA experiments. It connects cap orientation, translation initiation, IVT parameters, and assay interpretation for researchers studying cell viability, proliferation, and cytotoxicity.
-
α-Linolenic Acid: Reproducible Research Workflows
2026-10-01
Build controlled ALA experiments around lipid uptake, β-oxidation, membrane incorporation, and signaling rather than treating it as a generic supplement. This guide connects practical cell-based workflows with cardiovascular, inflammation, and cancer research while clearly separating ALA evidence from newer arachidonic-acid immunology findings.
-
SERPINB5 in Lung Adenocarcinoma: Biomarker and EMT
2026-10-01
This study integrates multi-cohort database analysis, clinical validation, and LUAD cell experiments to position SERPINB5 as a prognostic biomarker with tumor-promoting activity. Its findings connect elevated SERPINB5 expression with poor overall survival and with proliferation, migration, invasion, and epithelial–mesenchymal transition, while also identifying practical considerations for independent qPCR validation.
-
EdU Imaging Kits (Cy5) for S-Phase Studies
2026-09-30
EdU Imaging Kits (Cy5) provide a morphology-preserving way to quantify DNA synthesis in microscopy and flow cytometry workflows. This guide translates ovarian granulosa-cell findings into practical assay design, optimization, and troubleshooting decisions.
-
T7 RNA Polymerase: From Transcription to Translation
2026-09-30
T7 RNA Polymerase is more than a high-yield transcription reagent: its promoter recognition, initiation behavior, and transcript-end control can determine whether cell-free RNA supports functional translation. New work on continuous tRNA synthesis shows how polymerase-aware design can connect in vitro transcription with synthetic-cell engineering, RNA vaccine production research, and antisense RNA and RNAi workflows.
-
Exo1 Workflows for Membrane Trafficking
2026-09-29
Exo1 enables acute, mechanism-distinct inhibition of ER-to-Golgi membrane traffic for cleaner exocytosis assays and ARF1 localization studies. This guide translates its product profile into practical workflows while showing how it can complement, but not replace, tumor extracellular vesicle research.
-
Entecavir for Acute Hepatitis B: Meta-Analysis
2026-09-29
This systematic review and meta-analysis compares lamivudine and Entecavir for severe acute hepatitis B, emphasizing the difference between virological response and clearance of acute infection. Its findings suggest that evidence for nucleoside analogues remains low quality overall, while the limited direct comparison favored Entecavir over lamivudine and warrants cautious interpretation.